Leveraging RNA-Seq for a robust, accurate measure of HLA calling for endpoints in clinical trials

Presentation from The 2017 Immuno-Oncology Summit In Boston, MA

Presented at The Immuno-Oncology Summit in August, 2017, this presentation highlights HLA typing in immunotherapy trials, including advantages and difficulties as well as types of HLA typing. This presentation also provides the benefits of HLAProfiler.

Victor Weigman, Ph.D., Director, Translational Genomics